Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Peer review reports

Original Submission
13 Aug 2017	Submitted	Original manuscript
25 Aug 2017	Reviewed	Reviewer Report - Hari Ananthula
11 Sep 2017	Reviewed	Reviewer Report - Alfred Balch
22 Sep 2017	Author responded	Author comments - Pravesh Kumar Bundhun
Resubmission - Version 2
22 Sep 2017	Submitted	Manuscript version 2
Publishing
15 Oct 2017	Editorially accepted
23 Oct 2017	Article published	10.1186/s40360-017-0175-0

Back to article page